A phase II study of bisantrene in advanced refractory breast cancer

An Eastern Cooperative Oncology Group pilot study

Abstract

THIRTY PATIENTS WITH ADVANCED REFRACTORY BREAST CANCER received bisantrene 260 mg/m² intravenously every 3 weeks. Reversible myelosuppression was the most commonly observed side effect. Four patients (13.3%) achieved objective partial response (90% confidence intervals 3–24%), while two patients (6.6%) had disease improvement with a PR + IMP rate of 19.9%. Seven additional patients (23.3%) had stabilization of disease. This drug has antitumor activity against breast cancer and warrants further study, particularly if problems with drug delivery are overcome.